Ask AI
ProCE Banner Activity

ANCHOR: Phase III Trial of Anlotinib or Bevacizumab With 1L Chemotherapy for RAS/BRAF Wild-Type Unresectable mCRC

Conference Coverage
Slideset

In the phase III ANCHOR trial, anlotinib or bevacizumab when used in combination with capecitabine and oxaliplatin as first-line therapy for patients with RAS/BRAF wild-type mCRC resulted in similar PFS and safety outcomes.

Released: June 03, 2025

Expiration: December 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group